Drug Guidance for Subsidy 06/02/2026 Inavolisib in combination with palbociclib and fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended inavolisib, in combinat... See all × 06/02/2026 Inavolisib in combination with palbociclib and fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended inavolisib, in combination with palbociclib and fulvestrant, for inclusion on the MOH List of Subsidised Drugs for PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine therapy. The decision was based on the unfavourable cost effectiveness compared with palbociclib plus fulvestrant at the proposed price, and the unacceptable price-volume agreement proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for inavolisib are provided in the Annex.
ORAL Select a brand starting with the letter: I ITOVEBI FILM COATED TABLETS 3MG [SIN17403P] ITOVEBI FILM COATED TABLETS 9 MG [SIN17404P]